This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in
patients with advanced solid tumors. The study consists of several study modules, each
evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK),
pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in
combination with anti-cancer agents.